Table 1.
Overview of the included studies in the meta-analysis.
| First author | Year | Cancer types | Cancer status | Study setting | ICI arm | Non-ICI arm | Number of patients | |||
|---|---|---|---|---|---|---|---|---|---|---|
| ICI | Non-ICI | |||||||||
| All | Myositis | All | Myositis | |||||||
| André (12) | 2020 | MSI-High Colorectal | Advanced | First-line | Pembrolizumab | Chemotherapy | 153 | 1 | 143 | 0 |
| Eggermont (13) | 2018 | Melanoma | Resected stage III | Adjuvant | Pembrolizumab | Placebo | 509 | 1 | 502 | 0 |
| Ferris (14) | 2016 | HNSCC | Recurrent | After platinum-based chemotherapy | Nivolumab | MTX, Docetaxel, or Cetuximab | 236 | 0 | 111 | 1 |
| Galsky (15) | 2020 | Urothelial | Metastatic | First-line | Atezolizumab + platinum-based chemotherapy | Placebo + platinum-based chemotherapy | 453 | 3 | 390 | 1 |
| Gutzmer (16) | 2020 | Melanoma | Advanced | First-line | Atezolizumab | Placebo | 230 | 1 | 281 | 0 |
| Kojima (17) | 2020 | Esophageal | Advanced | Second-line | Pembrolizumab | Chemotherapy | 314 | 1 | 296 | 0 |
| Kuruvilla (18) | 2021 | HL | Relapsed or refractory | Second or later line | Pembrolizumab | Brentuximab | 148 | 1 | 152 | 0 |
| Miles (19) | 2021 | TNBC | Metastatic | First-line | Atezolizumab + PTX | Placebo + PTX | 431 | 1 | 218 | 0 |
| Mittendorf (20) | 2020 | TNBC | Stage II-III | First-line | Atezolizumab | Placebo | 164 | 1 | 167 | 0 |
| Moore (21) | 2021 | Ovarian | Ssage III-IV | Neoadjuvant | Atezolizumab + CBDCA + PTX + Bevacizumab | Placebo + CBDCA + PTX + Bevacizumab | 642 | 4 | 644 | 5 |
| Powles (22) | 2018 | Urothelial | Advanced or metastatic | After platinum-based chemotherapy | Atezolizumab | Vinflunine, PTX, or Docetaxel | 459 | 1 | 443 | 0 |
| Powles (23) | 2020 | Urothelial | Advanced or metastatic | First-line | Avelumab + BSC | BSC alone | 344 | 1 | 345 | 0 |
| Reck (24) | 2016 | SCLC | Extensive-stage | First-line | Ipilimumab + CDDP/CBDCA + VP-16 | Placebo + CDDP/CBDCA + VP-16 | 562 | 2 | 561 | 0 |
| Rini (25) | 2019 | RCC | Advanced | First-line | Pembrolizumab + Axitinib | Sunitinib | 429 | 2 | 425 | 0 |
| Rini (26) | 2019 | RCC | Metastatic | First-line | Atezolizumab + Bevacizumab | Sunitinib | 451 | 1 | 446 | 0 |
| Rudin (27) | 2020 | SCLC | Stage IV | First-line | Pembrolizumab + EP | Placebo + EP | 223 | 1 | 223 | 0 |
| Schmid (28) | 2020 | TNBC | Stage II-III | First-line | Pembrolizumab + chemotherapy | Placebo + Chemotherapy | 781 | 3 | 389 | 0 |
| Winer (29) | 2021 | TNBC | Metastatic | Second or later line | Pembrolizumab | Chemotherapy | 309 | 1 | 292 | 0 |
MSI-H, microsatellite-instability–high; NSCLC, non-small cell lung cancer; HNSCC, head-and-neck squamous cell cancer; TNBC, triple-negative breast cancer; SCLC, small cell lung cancer; RCC, renal cell carcinoma; ICI, immune checkpoint inhibitor; PTX, paclitaxel; CBDCA, carboplatin; BSC, best supportive care; CDDP, cisplatin; VP-16, etoposide; EP, etoposide and platinum; MTX, methotrexate.